Over 30 years ago, the Kennedy Trust supported the early research and clinical trials that led to the discovery of anti-TNF therapy, a groundbreaking treatment that has improved the lives of millions of patients with musculoskeletal and inflammatory diseases across...

In 1985, Professors Sir Marc Feldmann and Sir Ravinder Maini identified Tumour Necrosis Factor alpha (TNFα) as a key component in diseases of inflammation. They suggested treatment for such diseases could improve by blocking TNFα. This discovery led to decades...